Vit D supps "reduce fracture risk up to 20%"

29 March 2009

Oral vitamin D supplements at a dose of at least 400 international units per day are associated with a reduced risk of bone fractures in  older adults, according to results of a meta-analysis published in the  March 23 issue of Archives of Internal Medicine.

"The anti-fracture benefits of vitamin D have been questioned by  several recent trials," the authors write, adding that "factors that may  obscure a benefit of vitamin D are low adherence to treatment, low dose  of vitamin D or the use of less potent ergocalciferol (vitamin D2)."

The scientists performed a meta-analysis on 12 previously-published  clinical trials involving 42,279 participants and found that vitamin D  supplements decreased the risk of non-vertebral fractures by 14% and of  hip fractures by 9%. The authors then pooled the results of only nine  trials in which subjects received doses of more than 400  international units per day. At this higher dosage, vitamin D reduced  non-vertebral fractures by 20% and hip fractures by 18%. Lower doses did  not cut the risk of either fracture type. A greater reduction was also  seen among trial participants whose blood levels of 25-hydroxyvitamin  D - a commonly used measure of blood vitamin D levels - achieved a  greater increase.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight